vs
Side-by-side financial comparison of Amarin Corp plc (AMRN) and AMERISAFE INC (AMSF). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $45.1M, roughly 1.8× Amarin Corp plc). AMERISAFE INC runs the higher net margin — 10.2% vs -23.3%, a 33.5% gap on every dollar of revenue. On growth, AMERISAFE INC posted the faster year-over-year revenue change (10.3% vs 7.0%). Over the past eight quarters, AMERISAFE INC's revenue compounded faster (2.8% CAGR vs -18.3%).
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
AMRN vs AMSF — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $45.1M | $80.1M |
| Net Profit | $-10.5M | $8.1M |
| Gross Margin | — | — |
| Operating Margin | 35.5% | — |
| Net Margin | -23.3% | 10.2% |
| Revenue YoY | 7.0% | 10.3% |
| Net Profit YoY | 33.0% | -9.0% |
| EPS (diluted) | — | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $45.1M | $80.1M | ||
| Q4 25 | $49.2M | $81.6M | ||
| Q3 25 | $49.7M | $82.0M | ||
| Q2 25 | $72.7M | $81.1M | ||
| Q1 25 | $42.0M | $72.6M | ||
| Q4 24 | $62.3M | $74.0M | ||
| Q3 24 | $42.3M | $78.7M | ||
| Q2 24 | $67.5M | $75.8M |
| Q1 26 | $-10.5M | $8.1M | ||
| Q4 25 | $-1.2M | $10.4M | ||
| Q3 25 | $-7.7M | $13.8M | ||
| Q2 25 | $-14.1M | $14.0M | ||
| Q1 25 | $-15.7M | $8.9M | ||
| Q4 24 | $-48.6M | $13.2M | ||
| Q3 24 | $-25.1M | $14.3M | ||
| Q2 24 | $1.5M | $11.0M |
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 15.6% | ||
| Q3 25 | -22.4% | 21.3% | ||
| Q2 25 | -22.0% | 21.5% | ||
| Q1 25 | -39.9% | 15.5% | ||
| Q4 24 | -84.3% | 22.7% | ||
| Q3 24 | -59.5% | 22.6% | ||
| Q2 24 | -0.8% | 18.1% |
| Q1 26 | -23.3% | 10.2% | ||
| Q4 25 | -2.5% | 12.8% | ||
| Q3 25 | -15.6% | 16.9% | ||
| Q2 25 | -19.4% | 17.2% | ||
| Q1 25 | -37.4% | 12.3% | ||
| Q4 24 | -78.0% | 17.8% | ||
| Q3 24 | -59.4% | 18.2% | ||
| Q2 24 | 2.3% | 14.5% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $0.00 | $0.55 | ||
| Q3 25 | $-0.02 | $0.72 | ||
| Q2 25 | $-0.03 | $0.73 | ||
| Q1 25 | $-0.04 | $0.47 | ||
| Q4 24 | $-0.12 | $0.69 | ||
| Q3 24 | $-0.06 | $0.75 | ||
| Q2 24 | $0.00 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $307.8M | $34.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $246.6M |
| Total Assets | $645.8M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $307.8M | $34.2M | ||
| Q4 25 | $302.6M | $61.9M | ||
| Q3 25 | $286.6M | $54.7M | ||
| Q2 25 | $298.7M | $48.5M | ||
| Q1 25 | $281.8M | $44.8M | ||
| Q4 24 | $294.2M | $44.1M | ||
| Q3 24 | $305.7M | $63.7M | ||
| Q2 24 | $306.7M | $30.6M |
| Q1 26 | — | $246.6M | ||
| Q4 25 | $459.3M | $251.6M | ||
| Q3 25 | $458.9M | $274.8M | ||
| Q2 25 | $464.9M | $265.6M | ||
| Q1 25 | $473.7M | $260.8M | ||
| Q4 24 | $486.2M | $257.3M | ||
| Q3 24 | $531.4M | $314.4M | ||
| Q2 24 | $551.9M | $301.0M |
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $1.1B | ||
| Q3 25 | $659.8M | $1.2B | ||
| Q2 25 | $670.1M | $1.2B | ||
| Q1 25 | $655.7M | $1.2B | ||
| Q4 24 | $685.3M | $1.2B | ||
| Q3 24 | $750.6M | $1.3B | ||
| Q2 24 | $799.9M | $1.2B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
AMSF
Segment breakdown not available.
